Tidal Investments LLC boosted its position in shares of Centene Co. (NYSE:CNC – Free Report) by 21.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,117 shares of the company’s stock after purchasing an additional 7,549 shares during the period. Tidal Investments LLC’s holdings in Centene were worth $3,171,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Park Place Capital Corp boosted its holdings in shares of Centene by 1,190.0% in the 3rd quarter. Park Place Capital Corp now owns 387 shares of the company’s stock worth $29,000 after acquiring an additional 357 shares in the last quarter. WR Wealth Planners LLC boosted its stake in Centene by 41.4% in the second quarter. WR Wealth Planners LLC now owns 468 shares of the company’s stock worth $31,000 after purchasing an additional 137 shares in the last quarter. Chris Bulman Inc bought a new stake in shares of Centene during the second quarter worth $33,000. Crewe Advisors LLC increased its stake in shares of Centene by 174.3% in the second quarter. Crewe Advisors LLC now owns 683 shares of the company’s stock valued at $45,000 after buying an additional 434 shares in the last quarter. Finally, Private Trust Co. NA raised its holdings in shares of Centene by 75.3% in the third quarter. Private Trust Co. NA now owns 773 shares of the company’s stock valued at $58,000 after buying an additional 332 shares during the last quarter. 93.63% of the stock is owned by institutional investors.
Insider Transactions at Centene
In other Centene news, CEO Sarah London bought 4,117 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was acquired at an average price of $60.80 per share, with a total value of $250,313.60. Following the completion of the transaction, the chief executive officer now owns 667,229 shares in the company, valued at approximately $40,567,523.20. This trade represents a 0.62 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew Lynn Asher purchased 17,200 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were acquired at an average cost of $58.14 per share, for a total transaction of $1,000,008.00. Following the completion of the transaction, the chief financial officer now directly owns 486,847 shares in the company, valued at approximately $28,305,284.58. This represents a 3.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.33% of the stock is owned by insiders.
Analysts Set New Price Targets
Check Out Our Latest Report on Centene
Centene Price Performance
Shares of NYSE CNC opened at $59.42 on Friday. The company has a fifty day moving average price of $62.02 and a 200 day moving average price of $68.59. Centene Co. has a 1-year low of $55.03 and a 1-year high of $81.42. The firm has a market cap of $30.00 billion, a PE ratio of 10.32, a PEG ratio of 0.78 and a beta of 0.46. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64.
Centene Profile
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.
Read More
- Five stocks we like better than Centene
- Insider Buying Explained: What Investors Need to Know
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Roth IRA Calculator: Calculate Your Potential Returns
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Golden Cross Stocks: Pattern, Examples and Charts
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.